Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-26T20:05:40.707Z Has data issue: false hasContentIssue false
  • English
  • Français

Investigation of serum levels of sortilin in response to antidepressant treatment

Published online by Cambridge University Press:  08 May 2017

Henriette Nørmølle Buttenschøn ,
Marit Nielsen ,
Simon Glerup  and
Ole Mors
Henriette Nørmølle Buttenschøn*
Affiliation:
Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark
Marit Nielsen
Affiliation:
Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark
Simon Glerup
Affiliation:
The Lundbeck Foundation Research Center, MIND, Aarhus University, Aarhus, Denmark
Ole Mors
Affiliation:
The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark Psychosis Research Unit, Aarhus University Hospital, Risskov, Denmark
*
*Henriette N. Buttenschøn, Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark. Tel: +45 7847 1163; Fax: +45 7847 1108; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

The identification of biomarkers for depression is of great clinical relevance as the diagnosis is currently subjective. Recent research points towards sortilin as a potential biomarker for depression, and the aim of the current study was to investigate the serum sortilin level in response to antidepressant treatment.

Methods

The study included 56 depressed individuals of which 41 responded to treatment. Depression scores and serum levels of sortilin were measured at baseline and after 12 weeks of antidepressant treatment. Statistical analyses were performed using Stata 13.

Results

The depression score and response to treatment were not predicted by the sortilin level. Likewise, we observed no significant change in serum sortilin levels following 12 weeks of antidepressant treatment. Furthermore, no association between the serum sortilin level and depression score was observed.

Conclusion

The results do not point towards sortilin as a state-dependent biomarker.

Keywords

antidepressant treatmentbiomarkerdepressionsortilin
Type
Short Communication
Information
Acta Neuropsychiatrica , Volume 30 , Issue 2 , April 2018 , pp. 111 - 116
Check for updates
Copyright
© Scandinavian College of Neuropsychopharmacology 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Sullivan, PF, Neale, MC, Kendler, KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000;157:1552–1562.CrossRefGoogle ScholarPubMed
2. Pedersen, CB, Mors, O, Bertelsen, A et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry 2014;71:573–581.Google Scholar
3. Bilello, JA. Seeking an objective diagnosis of depression. Biomark Med 2016;10:861–875.CrossRefGoogle ScholarPubMed
4. Molendijk, ML, Spinhoven, P, Polak, M et al. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry 2014;19:791–800.Google Scholar
5. Teng, HK, Teng, KK, Lee, R et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 2005;25:5455–5463.Google Scholar
6. Vaegter, CB, Jansen, P, Fjorback, AW et al. Sortilin associates with Trk receptors to enhance anterograde transport and neurotrophin signaling. Nat Neurosci 2011;14:54–61.CrossRefGoogle ScholarPubMed
7. Glerup, S, Nykjaer, A, Vaegter, CB. Sortilins in neurotrophic factor signaling. Handb Exp Pharmacol 2014;220:165–189.CrossRefGoogle ScholarPubMed
8. Alemany, S, Ribases, M, Vilor-Tejedor, N et al. New suggestive genetic loci and biological pathways for attention function in adult attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2015;168:459–470.Google Scholar
9. Baum, AE, Akula, N, Cabanero, M et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008;13:197–207.CrossRefGoogle ScholarPubMed
10. Hyde, CL, Nagle, MW, Tian, C et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nat Genet 2016;48:1031–1036.CrossRefGoogle ScholarPubMed
11. Lambert, JC, Ibrahim-Verbaas, CA, Harold, D et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 2013;45:1452–1458.Google Scholar
12. Buttenschon, HN, Demontis, D, Kaas, M et al. Increased serum levels of sortilin are associated with depression and correlated with BDNF and VEGF. Transl Psychiatry 2015;5:e677.CrossRefGoogle ScholarPubMed
13. Zhou, L, Xiong, J, Lim, Y et al. Upregulation of blood proBDNF and its receptors in major depression. J Affect Disord 2013;150:776–784.Google Scholar
14. Stelzhammer, V, Guest, PC, Rothermundt, M et al. Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients. Eur Neuropsychopharmacol 2013;23:1199–1207.CrossRefGoogle ScholarPubMed
15. Belzeaux, R, Formisano-Treziny, C, Loundou, A et al. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J Psychiatr Res 2010;44:1205–1213.CrossRefGoogle ScholarPubMed
16. Uher, R, Maier, W, Hauser, J et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 2009;194:252–259.Google Scholar
17. Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.CrossRefGoogle ScholarPubMed
18. World Health Organization. Diagnosis and clinical measurement in psychiatry. A reference manual for SCAN. 1998.Google Scholar
19. Devader, C, Roulot, M, Moreno, S et al. Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients. J Affect Disord 2017;208:443–447.Google Scholar
Supplementary material: Image

Buttenschøn supplementary material

Supplementary Figure

Download Buttenschøn supplementary material(Image)
Image 3.4 MB